95417 ⎘
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups - in which the condensed system contains two hetero rings Peri-condensed systems
Substituted heterocyclic compounds and methods of use
#302Purine derivatives as kinase inhibitors
#303PARP inhibitor compounds, compositions and methods of use
#304Compounds, methods and pharmaceutical compositions for inhibiting PARP
#305Organic compounds
#306Pyrrolo-quinoxalinone derivatives as antibacterials
#307ORGANIC ELECTROLUMINESCENT DEVICE, AN AZEPINE COMPOUND, AND A METHOD FOR MAKING THE SAME
#308Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators
#309Sulfonyl-indole derivatives
#310BENZAZEPIN-2(1H)-ONE DERIVATIVES
#311HCV NS5B inhibitors
#312Tricyclic anilide spirolactam CGRP receptor antagonists
#313Azaaromatic compounds having azafluoranthene skeletons and organic electroluminescent devices made by using the same
#314Diimide-based semiconductor materials and methods of preparing and using the same
#315COMPOUNDS
#316ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS
#317BENZAZEPIN-2(1H)-ONE DERIVATIVES
#318Compounds, methods and pharmaceutical compositions for inhibiting PARP
#319CYCLOPENTA[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES
#320Anxiolytic Agents With Reduced Sedative And Ataxic Effects
#321Organic electroluminescent device, and azepine compound and method for producing the same
#322Novel heterocyclic compound
#323Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
#324Naphthalene derivatives and colorants for keratin fibers containing these compounds
#325Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
#326Novel antibacterial agents
#327Therapeutic compounds
#328Process for the preparation of 1,2,3,4,8,9,10, 10a-octahydro-7bH-cyclopenta[b][1,4]diazepino-[6,7,1-hi]indole derivatives
#329Anxiolytic agents with reduced sedative and ataxic effects
#330ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS
#331Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
#332Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity
#333Tricyclic indole derivatives and their use in the treatment of alzheimer's disease
#334Compositions and methods for treatment of cancer
#335Substituted heterocycle fused γ-carbolines
#336Compounds and their uses
#337Fused indazole compounds
#338Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-ce]indol-6-one
#339Method of preparing poly(ADP-ribose) polymerases inhibitors
#340Granzyme b inhibitors
#341Tricyclic inhibitors of poly(ADP-ribose) polymerases
#342Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
#343Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
#344Compounds and their uses
#345Plant extracts and alkaloids having antitussive activity
#346Substituted heterocyclic compounds and methods of use
#347Compounds and their uses
#348Therapeutic compounds
#349Piperidine compounds
#350Purine derivatives as kinase inhibitors
#351Tricyclic inhibitors of poly(ADP-ribose) polymerases
#352Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
#353Cyclohepta[b][1,4]diazepino[6,7,1,-hi]indoles and derivatives
#354Benzimidazole derivatives, preparation and therapeutic use thereof
#355Methods and kits using extended rhodamine dyes
#356Compounds, methods and pharmaceutical compositions for inhibiting PARP
#357Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives